Coadministration with Delstrigo has not been studied. Coadministration of doravirine (100 mg once daily) and ledipasvir/sofosbuvir (90/400 mg once daily) increased doravirine AUC, Cmax and Cmin by 15%, 11% and 24%, respectively. This small increase is not considered clinically meaningful. Doravirine did not significantly alter ledipasvir or sofosbuvir exposures. Similarly, coadministration of lamivudine and ledipasvir/sofosbuvir had no significant effect on the pharmacokinetics of lamivudine, ledipasvir and sofosbuvir. However, coadministration of tenofovir-DF with ledipasvir/sofosbuvir has been shown to increase tenofovir concentrations, especially when used with an HIV regimen containing a pharmacokinetic enhancer (ritonavir or cobicistat). Increased tenofovir exposure has also been shown with HIV regimens containing efavirenz and rilpivirine. The safety of increased tenofovir concentrations in these settings has not been established. The potential risks and benefits associated with coadministration should be considered, particularly in patients at increased risk of renal dysfunction. For patients receiving a boosted HIV protease inhibitor, consider an alternative HCV or antiretroviral therapy. If coadministration is necessary, monitor for tenofovir-associated adverse reactions, including frequent renal monitoring.